Phase 1/2 study of the safety and efficacy of APL-101, a specific c-MET inhibitor

S. H. Kizilbash, A. El-Khoueiry, R. E. Lerner, P. C. Ma, M. Almubarak, K. Mody, M. E. Burkard, M. Guarino, J. Jenab-Wolcott, N. Sankar, G. Choy, L. Espiritu, X. Zhang, A. Luria, F. Benedetti, E. C. Dees

Research output: Contribution to journalArticlepeer-review

Original languageEnglish (US)
Pages (from-to)S11-S12
JournalEuropean Journal of Cancer
StatePublished - Oct 2020

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this